Glucokinase

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Continuity, Diabetes, Entrepreneurship, Risk, C3, Non-alcoholic fatty liver disease, Epilepsy, FDA, CR2, Anticonvulsant, Inflammation, Neuron, Geographic atrophy, Conference, Paratriathlon, Pain, European, Disease, Cmax, Glycated hemoglobin, Trigeminal neuralgia, FGF21, Steatosis, Therapy, Computational biology, Exophthalmos, TED, Diplopia, Varenicline, Smoking, Injection, AAV, CNS, DSM-IV codes, Patient, Graves' ophthalmopathy, Medicine, Seizure, Glucokinase, Neurology, CR1, NASH, Insulin, Brain, GMP, Trigeminal nerve, Ophthalmology, Pathology, Fibrosis, Pharmaceutical industry

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

Hua Medicine Announces 2023 Interim Results

Retrieved on: 
Friday, August 25, 2023
IGT, DREAM, National Healthcare Security Administration, Rat, Type 2 diabetes, Diabetes, Obesity, Progress, Hong Kong Exchanges and Clearing, Hospital, Patient, NGT, Fructose, American Diabetes Association, ADA, Disease, Pharmacy, Drug discovery, DSM-IV codes, Pancreas, Research, Homeostasis, Kidney, PPG, FKI, Liver, Growth, IND, Fatty liver disease, Endocrinology, DPP-4, Stroke, Chinese University of Hong Kong, MAH, Type 2, Metformin, CUHK, IVD, STA, DKD, Glucokinase, Probability, Metabolism, Liver disease, GK, Nature Communications, SEED, Trial of the century, TIR, Plasma protein binding, GKA, National Healthcare, Physician, AI, Bank, NRDL, Medicine, Congenital hyperinsulinism, Medical device, Pharmaceutical industry, Cryptocurrency, Bayer, T2D

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

Key Points: 
  • Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").
  • Dr. Li Chen, the founder and CEO of Hua Medicine, said, "the first half of 2023 was a critical stage for Hua Medicine to begin commercialization.
  • The revenue of Hua Medicine for the first half of 2023 was RMB70.3 million, which was an increase of approximately 299.6% comparing to the second half of 2022.
  • This article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product.

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Retrieved on: 
Tuesday, June 7, 2022
DREAM, Woman, National Medical Products Administration, GK, Company, FPG, GKA, Observation, DAWN, Research, Jak Airport, ADA, CEO, Education, Disease, World Diabetes Day, Type 2 diabetes, Insulin resistance, Patient, Glycated hemoglobin, Insulin, Metformin, Trial of the century, Chinese, Glucokinase, Type 2, Association, American Diabetes Association, Department, Public health, Hospital, NDA, Blood, Homeostasis, Drug development, Chinese University of Hong Kong, Attention, Glucose clamp technique, China-Japan Friendship Hospital, WIN, SEED, Pharmaceutical industry, Epidemiology, Diabetes, T2D

A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

Key Points: 
  • A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).
  • Another clinical study called SENSITIZE also provided clinical scientific data of dorzagliatin in improving insulin secretion and glucose sensitivity.
  • The study results, using glucose clamp technique, showed that dorzagliatin can significantly improve second phase insulin secretion and glucose sensitivity in GCK-MODY patients and can significantly improve basal insulin secretion rates in patients with recent onset T2D.
  • Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China.

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Retrieved on: 
Friday, May 13, 2022
Diabetes, JAMA, Nature Reviews Drug Discovery, Company, Glucose, National Medical Products Administration, BMJ, Blood, Journal, Drug discovery, American Diabetes Association, GSIS, Pancreas, Medical college, Patient, Hypoglycemia, Homeostasis, Phase, NEJM, DAWN, Liver, Medical journal, Nanjing University, GKA, The New England Journal of Medicine, Trial of the century, Research, FPG, ADA, GK, NMPA, Safety, Insulin, Glucagon, NDA, American Medical Association, The Lancet, Metformin, Glucokinase, Insulin resistance, SEED, Medical Center, Hong Kong Stock Exchange, Inborn errors of metabolism, Glycated hemoglobin, Nature Medicine, Pharmaceutical industry, Medical device, Endocrinology, T2D, Lancet

The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.

Key Points: 
  • The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.
  • Before, the results of the Phase II clinical trial of dorzagliatin were published in the advanced medical journal The Lancet Diabetes and Endocrinology.
  • These two newly published papers present the Phase III results of the SEED study and the DAWN study of dorzagliatin, respectively.
  • Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs.

Hua Medicine Announces 2021 Annual Results

Retrieved on: 
Thursday, March 17, 2022
DREAM, People, Trial of the century, Solution, National Medical Products Administration, Technology, DAWN, Conference, LSE Alternative Investment Conference, NMPA, Big data, CEO, Diabetes, New Drug Application, Type 2 diabetes, SEED, GKA, NDA, Homeostasis, New Silk Road Initiative, Conditional sentence, American Diabetes Association, Republic, Metformin, Type 2, 52 Weeks Make A Year, Social Problems, Artificial intelligence, Research, Drug development, Marketing, Patient, Health, Glucokinase, Type 1, Wuxi, Disease, Glycated hemoglobin, Insulin, Company, Belt, Pharmaceutical industry, Medical device, T2D, Sitagliptin, Bayer

SHANGHAI, CHINA, Mar 17, 2022 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period").

Key Points: 
  • SHANGHAI, CHINA, Mar 17, 2022 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period").
  • Dr. Li CHEN, the founder, CEO and Chief Scientific Officer of Hua Medicine, said, "2021 was a breakthrough year for Hua Medicine.
  • Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs.
  • Hua Medicine teams up with global high caliber people and integrates global resources to explore breakthrough technologies and products, and accelerate global innovation in diabetes care.

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Retrieved on: 
Sunday, September 26, 2021
DREAM, Neurodegeneration, Type 2, NDA, Stock exchange, T2DM, Conference, Diabetes, Patient, BMJ, Association, Glycated hemoglobin, Metformin, American Diabetes Association, NASH, CEO, Observational study, National Medical Products Administration, Company, Prevalence, SEED, Disease, Trial of the century, Hong Kong Stock Exchange, Glucokinase, Intelligence, Research, Big data, Insulin, 52 Weeks Make A Year, Safety, Insulin resistance, Prediabetes, Kaplan–Meier estimator, Type 2 diabetes, LSE Alternative Investment Conference, Department, Pharmaceutical industry

The SEED study is a Phase III registered clinical study of dorzagliatin monotherapy in drug-naive Type 2 diabetes patients to observe its long-term efficacy and safety.

Key Points: 
  • The SEED study is a Phase III registered clinical study of dorzagliatin monotherapy in drug-naive Type 2 diabetes patients to observe its long-term efficacy and safety.
  • The researchers comprehensively evaluated the subjects and set their individual HbA1c control goals, and the results of the research showed that the subjects had a 52-week glucose remission rate of 65.2% (95% CI, 53.4%, 77.0%) [1] during the research period.
  • The DREAM study explores the possibility of oral dosing in diabetes remission and is of great significance in expanding the treatment options for Type 2 diabetes."
  • Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes.

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Retrieved on: 
Wednesday, September 15, 2021
Insulin, Metformin, NDA, National Medical Products Administration, CEO, Efficiency, Sinopharm Group, Marketing, Diabetes, Ecosystem, Patient, Shanghai Stock Exchange, Company, Type 2, Medicine, GKA, Bayer, T2DM, Homeostasis, Disease, New Drug Application, HK, T2D, Glucokinase, City, Stock exchange, NMPA, News, Type 2 diabetes, Partnership, Hong Kong Stock Exchange, Pharmaceutical industry

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.

Hua Medicine Announces 2020 Interim Results

Retrieved on: 
Thursday, August 19, 2021
Company, Type 1, Diabetes, CDE, SEED, ADA, Bayer, Center, National Medical Products Administration, American Diabetes Association, DAWN, CSO, Diabetic nephropathy, Research, CMO, Type 2 diabetes, Disease, Metformin, Glucokinase, NDA, Homeostasis, T2DM, NMPA, Review, Type 2, Insulin resistance, Patient, Center for Drug Evaluation and Research, CEO, New Drug Application, Sitagliptin, Insulin, GKA, Technology, DKD, Pharmaceutical industry, Animal

SHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").

Key Points: 
  • SHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").
  • In the first half of 2021, Hua Medicine reached a breakthrough milestone in preparing for dorzagliatin's commercialization.
  • In anticipation of dorzagliatin commercialization, subject to approval of its NDA, in addition to its CMO partnerships, Hua Medicine has also established Hua Medicine drug manufacture company at Shanghai Lingang Special Area for ensuring adequate dorzagliatin commercial supply.
  • This article contains the statements regarding the future expectation, plan and prospects for Hua Medicine and the investigational product.

Detailed Insights on Glucokinase - H2 2020 Pipeline Review - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 6, 2021
Pharmaceutical, Health, Oncology, Branches of biology, Glucokinase, Hexokinase, Chemistry, Biochemistry, GCK, Enzyme, Glucose, Kinase, Enzyme activator

The "Glucokinase - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glucokinase - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 14 molecules.
  • The latest report Glucokinase - Pipeline Review, H2 2020, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration.

Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission

Retrieved on: 
Friday, March 19, 2021
Health sciences, Clinical research, Health, Clinical trial, Design of experiments, Food and Drug Administration, Pharmaceutical industry, Glucokinase, Medical research

Hua Medicine has become the first company in the world to complete clinical development of a glucokinase activator.

Key Points: 
  • Hua Medicine has become the first company in the world to complete clinical development of a glucokinase activator.
  • The results of the two Phase III clinical trials demonstrated that dorzagliatin has long-term sustained efficacy, and good safety and tolerability profiles.
  • Dorzagliatin has progressed from 0 to 1 - from a disruptive scientific theory to a potential commercially viable product, propelling Hua Medicine into a new stage of development.
  • Despite the pandemic Hua Medicine has still achieved several milestones and breakthroughs in clinical trials and in the prepartion for drug commercialization.